Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop (2024)

Chapter: Appendix B: Workshop Agenda

Visit NAP.edu/10766 to get more information about this book, to buy it in print, or to download it as a free PDF.
Previous Chapter: Appendix A: Statement of Task
Page 47 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel

Appendix B

Workshop Agenda

OCTOBER 17, 2023

8:00 am Session 1: Rationale and Objectives for Public–Private Partnerships in the Clinical Cancer Research Enterprise
Co-Moderators:
  • Roy Herbst, Yale University
  • Richard L. Schilsky, University of Chicago
Welcome and Introductory Remarks
  • Roy Herbst, Yale University
  • Richard L. Schilsky, University of Chicago
Keynote Presentations
  • Julie Gerberding, Foundation for the National Institutes of Health
  • Dinah Singer, National Cancer Institute
Industry Perspective
  • Aida Habtezion, Pfizer Inc. (Virtual)
Patient Advocacy Perspective
  • Ellen Sigal, Friends of Cancer Research
Food and Drug Administration Perspective
  • Richard Pazdur, FDA Oncology Center of Excellence
Page 48 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
Panel Discussion with Speakers and Additional Panelists
  • Gail Eckhardt, Baylor College of Medicine
  • William Dahut, American Cancer Society
10:00 am Break
10:15 am Session 2: Exemplars of Public–Private Partnerships in Clinical Cancer Research
Co-Moderators:
  • Edith Perez, Mayo Clinic and Bolt Biotherapeutics
  • Heidi Smith, Novartis Pharmaceuticals
Examples of Past and Ongoing Public–Private Collaborations in Oncology
Lung Cancer Master Protocol (Lung-MAP)
  • Roy Herbst, Yale University
PALbociclib CoLlaborative Adjuvant Study (PALLAS)
  • Erica Mayer, Dana-Farber Cancer Institute (Virtual)
  • Prash Gopalakrishna, Pfizer Inc. (Virtual)
Pragmatica-Lung Cancer Treatment Trial
  • Karen L. Reckamp, Cedars-Sinai Medical Center
  • Harpreet Singh, FDA Oncology Center of Excellence
Panel Discussion with Speakers and Additional Panelists
  • Stacey Adam, Foundation for the National Institutes of Health
  • Janet Dancey, Canadian Cancer Trials Group (Virtual)
  • Vassilis Golfinopoulos, European Organisation for Research and Treatment of Cancer (Virtual)
  • Meg Mooney, National Cancer Institute
  • Gwen Nichols, Leukemia and Lymphoma Society
12:15 pm Break
1:00 pm Session 3: Regulatory and Policy Considerations for Public–Private Partnerships for Clinical Cancer Research
Co-Moderators:
  • Gideon Blumenthal, Merck
  • Esther Krofah, Milken Institute and FasterCures
Page 49 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
National Clinical Trials Network (NCTN) Perspectives on Public–Private Partnerships for Cancer Research
  • James Doroshow, National Cancer Institute
FDA Perspective on Optimal Planning, Conduct, and Submission of Registration Intent Trials Conducted Through Public–Private Partnerships
  • Harpreet Singh, FDA Oncology Center of Excellence
Academia/Government Taskforce Perspective: How to Enhance Cooperation Between Agencies and Academia
  • Michael Morris, Memorial Sloan Kettering Cancer Center
Nonprofit Perspective: Patient Centeredness in Clinical Trial Design
  • Stacie Lindsey, Cholangiocarcinoma Foundation
Investor Perspective on Public–Private Partnerships for Cancer Research
  • Josh Bilenker, Treeline Biosciences
Panel Discussion with Speakers and Additional Panelists
  • Jeff Allen, Friends of Cancer Research
  • Charles Blanke, Oregon Health & Science University
  • John Byrd, University of Cincinnati
  • Gail Eckhardt, Baylor College of Medicine
3:10 pm Break
3:25 pm Session 4: Enhancing Data Sharing for Public–Private Partnerships for Clinical Cancer Research
Co-Moderators:
  • Otis W. Brawley, Johns Hopkins University
  • Kristen Rosati, Coppersmith Brockelman PLC
Introduction
  • Otis W. Brawley, Johns Hopkins University
  • Kristen Rosati, Coppersmith Brockelman PLC
The Role of Government in Data Sharing
  • Penny Burgoon, National Institutes of Health
Page 50 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
The Role of the Research Institution in Data Sharing
  • Barbara Bierer, Harvard University
The Role of the Patient in Data Sharing
The Role of the Patent Advocate
  • Gwen Nichols, Leukemia and Lymphoma Society
The Role of Health IT in Data Sharing
  • Deven McGraw, Invitae/Ciitizen
The Role of the Sponsor in Data Sharing
  • Geoffrey Oxnard, Loxo Oncology, Eli Lilly
The Role of the Funder in Data Sharing
  • Tony Hickson, Cancer Research UK/Cancer Research Horizons
The Role of Publications in Data Sharing
  • Kirsten Bibbins-Domingo, Journal of the American Medical Association (Virtual)
  • Eric Rubin, New England Journal of Medicine (Virtual)
Panel Discussion: Solutions for Facilitating Data Sharing
5:30 pm Adjourn

OCTOBER 18, 2023

8:00 am Session 5: Embedding Clinical Cancer Research in Health Care Delivery
Co-Moderators:
  • Neal Meropol, Flatiron Health
  • Lawrence Shulman, University of Pennsylvania Abramson Cancer Center
Community Based Research Consortia
Industry-Sponsored Consortium
  • Melissa Johnson, Sarah Cannon Research Institute (Virtual)
Page 51 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
NCI Community Oncology Research Program Consortium
  • Carolyn Y. Muller, University of New Mexico Comprehensive Cancer Center
American Society of Clinical Oncology Consortia
  • Elizabeth Garrett-Mayer, American Society of Clinical Oncology
Challenges and Opportunities for Public–Private Partnerships to Improve Access to Cancer Drugs and Reduce Outcome Disparities in Resource-Constrained Settings
  • Lawrence Shulman, University of Pennsylvania Abramson Cancer Center
Public–Private Partnerships to Support Postmarketing Clinical Research in Routine Care Settings
  • Neal Meropol, Flatiron Health
Considerations for Industry Partnerships in Support of Health Care Delivery Research
  • Craig Tendler, Johnson & Johnson (Virtual)
Panel Discussion with Speakers and Additional Panelist
  • Matthew Cooney, Tempus
10:00 am Break
10:15 am Session 6: Opportunities to Advance Progress in Public–Private Partnerships for Clinical Cancer Research
Co-Moderators:
  • Roy Herbst, Yale University
  • Richard L. Schilsky, University of Chicago
Panelists:
  • Session 1: Roy Herbst and Richard L. Schilsky
  • Session 2: Edith Perez and Heidi Smith
  • Session 3: Gideon Blumenthal and Esther Krofah
  • Session 4: Otis W. Brawley (Virtual) and Kristen Rosati
  • Session 5: Neal Meropol and Lawrence Shulman
Page 52 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
11:20 am Concluding Remarks
Planning Committee Co-Chairs:
  • Roy Herbst, Yale University
  • Richard L. Schilsky, University of Chicago
11:30 am Adjourn
Page 47 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
Page 47
Page 48 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
Page 48
Page 49 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
Page 49
Page 50 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
Page 50
Page 51 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
Page 51
Page 52 Cite
Suggested Citation: "Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2024. Optimizing Public–Private Partnerships for Clinical Cancer Research: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/27758.
Save
Cancel
Page 52
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.